Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Nine Months ended December 31, 2012
Currency: Indian Rupees (INR) with U.S. Dollar (USD) convenience translation (Rate: 54.86 INR = 1 USD)
Business Overview: DRL is a leading India-based pharmaceutical company operating through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Principal markets include India, North America, Russia, and Europe.
Key Financial Metrics
Amounts in millions of INR unless otherwise noted.
| Metric | 9 Months Ended Dec 31, 2012 | 9 Months Ended Dec 31, 2011 | 3 Months Ended Dec 31, 2012 | 3 Months Ended Dec 31, 2011 |
|---|---|---|---|---|
| Revenues | 82,866 | 70,153 | 28,651 | 27,692 |
| Gross Profit | 43,733 | 39,335 | 15,091 | 16,575 |
| Gross Margin | 53% | 56% | 53% | 60% |
| Operating Profit | 13,684 | 14,081 | 4,728 | 7,547 |
| Net Profit (Profit for Period) | 11,067 | 10,835 | 3,782 | 5,130 |
| Net Margin | 13% | 15% | 13% | 19% |
| EPS (Basic) | 65.19 INR | 63.95 INR | 22.27 INR | 30.26 INR |
| Cash from Operations | 10,741 | 9,313 | N/A | N/A |
| Cash & Equivalents (Dec 31, 2012) | 8,782 | 7,379 (Mar 31, 2012) | 8,782 | 7,379 (Mar 31, 2012) |
| Total Debt (Short + Long Term) | 36,824 | 32,209 (Mar 31, 2012) | 36,824 | 32,209 (Mar 31, 2012) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 18% for the nine months ended Dec 31, 2012, driven by growth in North America, India, Russia, and the PSAI segment. The PSAI segment grew 26% year-over-year.
- Profitability Decline: Despite revenue growth, Net Profit for the quarter ended Dec 31, 2012, dropped 26% compared to the prior year. This was primarily due to the expiration of the 180-day market exclusivity for Olanzapine in the U.S. (which contributed significant profit share in the prior year) and increased pricing pressures.
- Impairment Charges: The company recorded impairment losses of 507 million INR on intangible assets and 181 million INR on goodwill during the nine-month period. These were primarily related to the German subsidiary (betapharm) and the Italian subsidiary (Dr. Reddy's SRL) due to adverse market conditions and lower expected cash flows.
- Margin Compression: Gross margins declined from 60% to 53% in the quarter, attributed to the loss of high-margin exclusivity profits and competitive pricing pressures.
- Effective Tax Rate: The effective tax rate decreased significantly to 18.9% for the quarter (from 33.8% in the prior year) due to the realization of deferred tax assets and a lower proportion of profits taxed in high-tax jurisdictions.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management remains optimistic about long-term growth in North America, citing 31 products ranked in the top three market shares. The company plans to launch several key products in the fiscal year ending March 31, 2013.
- Acquisition Activity: DRL completed a tender offer for OctoPlus N.V., acquiring 93.18% of equity shares as of February 21, 2013. The company is currently allocating consideration to assets and liabilities.
- Regulatory Risks:
- U.S. FDA: A Detention Without Physical Examination (DWPE) alert on the Mexico facility was lifted in July 2012 after corrective actions were accepted.
- Patent Litigation: Ongoing litigation regarding Fexofenadine (settled in Jan 2013), Olanzapine in Canada (pending Supreme Court appeal), and Ibandronate Sodium (Roche appealed summary judgment in favor of DRL).
- Environmental & Tax Contingencies: Pending disputes regarding land pollution compensation in India and significant indirect tax disputes (Input Service Tax credits and Fuel Surcharge Adjustments). The company has recorded provisions for potential liabilities but believes further material loss is unlikely.
- Currency Risk: A subsequent event noted the devaluation of the Venezuelan Bolivar (VEF) in February 2013. While this creates foreign exchange exposure, the company expects pending exchange authorizations to largely offset the loss.
Investor Verification Checklist
- Exclusivity Impact: Verify the extent to which the loss of Olanzapine exclusivity profits impacts future quarterly comparisons and whether new product launches will offset this gap.
- Impairment Sustainability: Review the assumptions used for the impairment of German and Italian goodwill/intangibles to assess if further write-downs are likely given the competitive landscape in Europe.
- OctoPlus Integration: Monitor the allocation of purchase price and the integration progress of the OctoPlus acquisition to evaluate synergies.
- Legal Provisions: Assess the adequacy of provisions for the pending Fuel Surcharge Adjustment (FSA) litigation and indirect tax disputes in India.
- Working Capital: Analyze the Days Sales Outstanding (DSO) trend (86 days at Dec 31, 2012) to ensure collection efficiency remains stable despite revenue growth.